Search

Charles River Laboratories International Inc

Avatud

SektorTervishoid

203.05 -0.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

199.96

Max

203.85

Põhinäitajad

By Trading Economics

Sissetulek

2.9M

56M

Müük

-27M

1B

P/E

Sektori keskmine

592.3

78.892

Aktsiakasum

2.43

Kasumimarginaal

5.529

Töötajad

18,700

EBITDA

-23M

198M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-1.14% downside

Turustatistika

By TradingEconomics

Turukapital

1.2B

10B

Eelmine avamishind

203.24

Eelmine sulgemishind

203.05

Uudiste sentiment

By Acuity

100%

0%

362 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Charles River Laboratories International Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. dets 2025, 15:21 UTC

Tulu

Correction to Home Depot Outlook Headline on Dec. 9

23. dets 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23. dets 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 21:21 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara to Hold Deposit in Escrow

23. dets 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23. dets 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23. dets 2025, 21:13 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23. dets 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23. dets 2025, 19:13 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23. dets 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23. dets 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23. dets 2025, 17:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

23. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23. dets 2025, 17:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23. dets 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23. dets 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23. dets 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank: Closing Expected Around Mid-January

23. dets 2025, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23. dets 2025, 16:02 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23. dets 2025, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Erste Group Bank Receives Green Light for Acquisition in Poland

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23. dets 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Telefonica Doesn't Set Out Financial Details of Divestment

23. dets 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Telefonica: Deal Will Allow Focus on Core Markets

23. dets 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23. dets 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Charles River Laboratories International Inc Prognoos

Hinnasiht

By TipRanks

-1.14% langus

12 kuu keskmine prognoos

Keskmine 200.55 USD  -1.14%

Kõrge 225 USD

Madal 170 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Charles River Laboratories International Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

7

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

117.16 / 144.77Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

362 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat